{
    "clinical_study": {
        "@rank": "87188", 
        "arm_group": [
            {
                "arm_group_label": "Breast cancer patients", 
                "description": "Breast cancer patients and controls"
            }, 
            {
                "arm_group_label": "prostate cancer patients", 
                "description": "Prostate cancer patients and controls"
            }, 
            {
                "arm_group_label": "lung cancer patients"
            }, 
            {
                "arm_group_label": "colon cancer patients"
            }
        ], 
        "biospec_descr": {
            "textblock": "Blood will be sampled for FFA metabolites"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "Surgical removal of tumor at an early stage remains the primary treatment for most cancers.\n      However, there is currently no reliable screening blood test for detection of lung, colon,\n      or breast cancer. The Specific Aims are to: 1) assess the diagnostic accuracy of six FFA\n      metabolites to detect lung and colon cancer in surgical patients; 2)determine the rate and\n      extent to which FFA metabolites decrease over time after surgery for lung and colon cancer;\n      and, 3)determine the positive and negative predictive values and overall test accuracy for\n      diagnostic prostate and breast biopsies."
        }, 
        "brief_title": "Free Fatty Acid Metabolite Biomarkers for Cancer", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Prostate Cancer", 
            "Breast Cancer", 
            "Colon Cancer", 
            "Lung Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Colonic Neoplasms", 
                "Lung Neoplasms", 
                "Prostatic Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  potential breast cancer\n\n          -  patients who have early stages of breast cancer prior to surgery potential prostate\n             cancer lung cancer colon cancer\n\n        Exclusion Criteria:\n\n          -  1) Patients will be excluded from enrollment if they have severe liver disease (ALT\n             three times the upper limit of normal). Patients will also be excluded who have taken\n             aspirin or COX inhibitors within 48 hours of surgery. 2) Patients will be excluded if\n             a pathologic diagnosis is already available,from a previous needle biopsy\n             (coordinator will remain blinded). 3) Patients will be excluded have received\n             pre-procedure chemotherapy or radiotherapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Prostate cancer occurs only in men; conversely, breast cancer is almost exclusively a\n        disease of women. The non-cancer control patients for each type of cancer will be of the\n        same sex. We propose to study roughly comparable numbers of prostate and breast cancer\n        patients (and controls). Colon and lung cancers occur at similar rates in men and women.\n        We thus expect that about half of our total enrollment will be female."
            }
        }, 
        "enrollment": {
            "#text": "1176", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01692951", 
            "org_study_id": "12-306"
        }, 
        "intervention": {
            "arm_group_label": [
                "Breast cancer patients", 
                "prostate cancer patients", 
                "lung cancer patients", 
                "colon cancer patients"
            ], 
            "description": "We will obtain daily blood samples from cancer patients enrolled under Specific Aim 1 while they remain hospitalized, and an additional sample one week after surgery.", 
            "intervention_name": "blood sample", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 14, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Cleveland", 
                    "country": "United States", 
                    "state": "Ohio", 
                    "zip": "44195"
                }, 
                "name": "Cleveland Clinic"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "4", 
        "overall_contact": {
            "email": "ds@or.org", 
            "last_name": "Daniel Sessler, M.D.", 
            "phone": "216-444-4900"
        }, 
        "overall_contact_backup": {
            "email": "johnsor13@cf.org", 
            "last_name": "Roberta Johnson", 
            "phone": "216-444-9950"
        }, 
        "overall_official": {
            "affiliation": "The Cleveland Clinic", 
            "last_name": "Daniel Sessler, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The primary outcome for Specific Aim 1 will be the area under the ROC curve and 95% confidence interval for each metabolite.", 
                "measure": "Estimate predictive values for each type of cancer.", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "description": "One-week biomarker reduction from the preoperative value for each cancer.", 
                "measure": "Determine Biomarker reduction in blood samples", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }, 
            {
                "description": "To determine the area under the receiver operating characteristic curve (i.e., AUC) predicting prostate and breast cancer for each FFA metabolite, as well as the diagnostic test parameters: sensitivity, specificity, positive and negative predictive values.", 
                "measure": "Evaluate predictive values for each type of cancer.", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01692951"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Outcomes Research Consortium", 
            "investigator_full_name": "d sessler", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "The Cleveland Clinic", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "The Cleveland Clinic", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}